Related Experiment Video
Updated: Feb 10, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
The vagus neurometabolic interface and clinical disease
Emily Battinelli Masi1,2, Sergio Iván Valdés-Ferrer1,3, Benjamin Ethan Steinberg4
1Laboratory of Biomedical Sciences, The Feinstein Institute for Medical Research, Manhasset, NY, USA.
Abstract:
The nervous system both monitors and modulates body metabolism to maintain homoeostasis. In disease states such as obesity and diabetes, the neurometabolic interface is dysfunctional and contributes to clinical illness. The vagus nerve, in particular, with both sensory and motor fibres, provides an anatomical substrate for this interface. Its sensory fibres contain receptors for important circulating metabolic mediators, including leptin and cholecystokinin, and provide real-time information about these mediators to the central nervous system. In turn, efferent fibres within the vagus nerve participate in a brain-gut axis to regulate metabolism. In this review, we describe these vagus nerve-mediated metabolic pathways and recent clinical trials of vagus nerve stimulation for the management of obesity. These early studies suggest that neuromodulation approaches that employ electricity to tune neurometabolic circuits may represent a new tool in the clinical armamentarium directed against obesity.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Coronary Artery Disease III: Clinical Manifestations
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Protein-protein Interfaces
Protein-Protein Interfaces
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

